| MINERVA NEUROSCIENCES |
| USA |
| Gesundheit |
| US6033802058 / A3DMH5 |
| 4MNA (Frankfurt) / NERV (NASDAQ) |
| FRA:4MNA, ETR:4MNA, 4MNA:GR, NASDAQ:NERV |
| - |
| https://www.minervaneuros.. |
|
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of product candidates for central nervous system diseases. Its lead product candidate, roluperidone, targets negative symptoms i..
>Volltext.. |
| 209.94 Mio. EUR |
| 195.1 Mio. EUR |
| - |
| -13.08 Mio. EUR |
| -254.2 Mio. EUR |
| -23.22 EUR |
| 56.28 Mio. EUR |
| 71.39 Mio. EUR |
| -11.7 Mio. EUR |
| 35.98 |
| - |
| -18074.25% |
| - |
| - |
| - |
| - |
| MINERVA NEUROSCIENCES, MINERVA NEURO, MINERVA NEUROSCIENCE |
| 05.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|